ONESTOCK/SUMMIT-PARTNERS
21.5.2024 08:01:34 CEST | Business Wire | Press release
OneStock SAS, a leading provider of Order Management Systems (OMS), today announced a $72 million investment from global growth equity investor Summit Partners.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240520891262/en/
Founders Benoit Baccot and Romulus Grigoras, OneStock (Photo: Business Wire)
OneStock was founded in 2015 by CEO, Romulus Grigoras, and CTO, Benoit Baccot, to help retailers and brands navigate the increasing complexity of the omnichannel landscape and enhance overall customer experience. The company’s cloud-native solution provides a centralised platform designed to manage end-to-end order fulfillment and visibility and empower retailers to offer a seamless ‘buy anywhere, deliver anywhere, return anywhere’ experience to customers.
"Since the beginning, OneStock has been dedicated to creating smarter and more sustainable shopping experiences, and our partnership with Summit marks a thrilling new chapter in our journey, reaffirming our long-term commitment to innovation and growth in the retail technology space,” commented Mr. Grigoras. “With Summit's support and the benefit of their deep experience in the retail technology sector, we're poised to accelerate our growth even further. Our clear ambition is to emerge as the number one global leader in the OMS category.”
Offering a highly compelling customer ROI and a feature-rich, user-centric solution, OneStock has experienced robust, profitable growth in recent years, achieving a 2.5-fold increase in recurring revenue since 2021. The company has seen widespread adoption amongst major enterprise customers across diverse verticals, ranging from luxury goods to car parts, pet food to furniture, and from traditional B2C retailers to franchiser networks and B2B commerce. Today, more than 100 international retailers and brands across 25 countries leverage OneStock, with the platform facilitating over €2.5 billion in orders annually. OneStock customers include Yves Rocher, WHSmith, Intersport, ManoMano, and S.Oliver.
“With the proliferation of online and offline sales channels and consumers’ ever-increasing expectations for instant product availability and fulfillment, we believe a modern OMS has become a critical part of the retail supply chain. In our view, OneStock has developed the most intuitive, scalable and differentiated cloud-native OMS solutions, purpose-built to help brands and retailers to plan better, grow faster, sell more and waste less,” comments Steffan Peyer, a Managing Director at Summit Partners who will join the OneStock Board of Directors.
This new funding will be used to fuel OneStock’s continued international expansion, particularly into the U.S. market, and to help accelerate the company’s vision for a retail landscape where order management is seamless and easy. OneStock is a proud Adobe Gold Partner, one of the select few MACH-certified OMS providers in the MACH Alliance, and the first OMS with an official integration with Shopify. The company aims to become the easiest-to-integrate OMS in the market by expanding its partner relationships, by extending the comprehensive range of integrations offered in the OneStock Extensions Portal and by soon opening its platform to external agencies and customers seeking to develop additional extensions for particular use cases and verticals. In addition, the company plans to accelerate product development in a number of areas, including B2B, AI and circular economy initiatives.
“OneStock is known in the retail market for having an impressive track record of innovation, including what we believe are pioneering features such as gamification as part of its Ship from Store product, its advanced Business Intelligence Suite, and one of the most sophisticated Delivery Promise solutions in the industry,” said Nik Ohri, a Vice President at Summit Partners who will also join the OneStock Board of Directors.
“We are thrilled to partner with this highly experienced team, and we look forward to working with Romulus and Benoit to help accelerate their vision and expand the reach of OneStock’s impact globally.”
Mr. Grigoras added: “I want to extend my heartfelt thanks to the entire OneStock team and all of our partners and customers, whose hard work and collaboration have been instrumental in helping OneStock achieve this fantastic milestone. We remain committed to supporting the success of our customers as we continue to shape the future of retail!”
About OneStock
OneStock is Europe’s market-leading distributed order management system provider. We help retailers unlock their full omnichannel potential and power some of the world’s most convenient shopping experiences. Our cloud-native SaaS solution improves operational efficiency, increases online revenue and enhances customer experience.
A single view of inventory across all stock locations enables our clients to maximise sales opportunities, enhance fulfilment options, optimise order orchestration, create new omnichannel capabilities, seamlessly manage returns and analyse business performance. OneStock is a proud member of the MACH Alliance and provides best-of-breed solutions for many brands, including: Pets at Home, Jigsaw, Hackett, The Perfume Shop, Dune and Moss. For more information, visit onestock-retail.com.
About Summit Partners
Founded in 1984, Summit Partners is a global alternative investment firm with capital dedicated to growth equity, fixed income, and public equity opportunities. Summit invests across growth sectors of the economy and has invested in more than 550 companies in technology, healthcare, and other growth industries. Notable investments in the retail technology and marketing technology sectors include RELEX, Akeneo, Klaviyo, Optimove, Later and Mi9 Retail. Summit maintains offices in North America and Europe and invests in companies around the world. For more information, please see www.summitpartners.com or Follow on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240520891262/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom